vertailuparin
Vertailuparin is a synthetic anticoagulant belonging to the class of direct thrombin inhibitors. It is a peptidomimetic designed to selectively bind to and inhibit thrombin, a key enzyme in the coagulation cascade responsible for converting fibrinogen to fibrin, thereby forming blood clots. Its development was aimed at providing an alternative to existing anticoagulants with potentially improved pharmacokinetic and pharmacodynamic profiles.
The mechanism of action of vertailuparin involves reversible binding to both the active site and the exosite
Studies have investigated vertailuparin's efficacy and safety in different patient populations and clinical scenarios, including those